Luigi Mangione, the defendant accused of murdering UnitedHealthcare CEO Brian Thompson in December 2024, has withdrawn his formal notice to pursue a psychiatric defense in his Manhattan criminal case. The move, confirmed in court filings on June 18, leaves the legal strategy for his upcoming trial in flux, though experts suggest he may still attempt to introduce evidence of mental distress without the formal procedural requirements of a CPL 250.10 notice.
Why the Defense Withdrew the Notice
The defense team, led by attorney Karen Friedman Agnifilo, filed a notice under New York Criminal Procedure Law (CPL) 250.10 earlier this year, signaling an intent to argue "extreme emotional disturbance" (EED). According to court transcripts unsealed by Judge Gregory Carro, the defense sought to keep the proceedings surrounding this notice sealed because formally invoking EED requires a defendant to essentially admit to committing the underlying act. Agnifilo argued that such a public admission could prejudice Mangione’s defense in both state and federal jurisdictions. By withdrawing the notice, the defense effectively ended the immediate requirement to disclose psychiatric reports and expert evaluations to the prosecution.
Can a Psychiatric Defense Proceed Without Formal Notice?
While the withdrawal of the CPL 250.10 notice suggests a shift in tactics, legal observers note it does not preclude the defense from raising mental health issues during trial. Veteran defense attorney Ron Kuby, who represented Gigi Jordan in her 2010 high-profile manslaughter case, notes that EED is not strictly dependent on the filing of a 250.10 notice.
In the Jordan case, the defense successfully argued for a manslaughter conviction rather than murder without filing a formal psychiatric notice. As Kuby explained, if a defendant opts out of the 250.10 process, they avoid the court-ordered psychiatric interviews requested by the prosecution, though they also lose the ability to introduce certain expert testimony. Instead, the defense may rely on the defendant’s own testimony or evidence presented by the prosecution to convince a jury that the individual acted under the influence of extreme emotional distress.
How the Court is Managing Trial Security
Beyond the defense strategy, Judge Carro is addressing security concerns stemming from the high level of public interest in the case. Prosecutors with the Manhattan District Attorney’s office have raised alarms regarding the behavior of Mangione’s supporters in the courtroom. According to prosecutor Joel Seidemann, the state has expressed concerns about potential threats and the presence of individuals wearing disruptive clothing or carrying signs. Judge Carro has indicated that the court will strictly regulate courtroom decorum to ensure the integrity of the proceedings, with the possibility of an anonymous jury being impaneled to protect against outside influence.
Case Status and Legal Precedents
Mangione faces both state and federal charges related to the shooting of Brian Thompson, which occurred on a midtown Manhattan street on December 4, 2024. He has entered a plea of not guilty to all charges. The case has drawn national attention not only for the high-profile nature of the victim—the CEO of a major health insurer—but also for the intense public discourse surrounding the U.S. healthcare system.
- Current Status: The CPL 250.10 notice is withdrawn, meaning the prosecution is not currently entitled to a court-ordered mental health examination of Mangione.
- Legal Strategy: The defense retains the right to present evidence of mental state through other avenues, such as the defendant’s own testimony.
- Next Steps: Judge Carro continues to oversee discovery and pretrial motions, with the court maintaining a sealed status for various documents until further notice.
While legal experts like Gary Galperin of the Cardozo School of Law have suggested that the withdrawal of the notice likely signals a permanent pivot away from a formal psychiatric defense, the final strategy remains subject to the defense team’s discretion as the trial date approaches.